AXSM
HEALTHCAREAxsome Therapeutics Inc
AI Insight
What's Moving AXSM Today?
No stock-specific AI insight has been generated for AXSM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$96.09$260.19
$242.89
Fundamentals
Market Cap$12.8B
P/E Ratio—
EPS$-3.72
Dividend Yield—
Dividend / Share—
ROE-349.4%
Profit Margin-26.6%
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding51.5M
AXSM News
29 articles- Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional HoldingsTradingKey·Jun 19, 2026
- Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness MonthYahoo Finance·Jun 18, 2026
- Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $300.00 at TD CowenMarketBeat·Jun 17, 2026
- 3 Under-the-Radar Stocks to Buy and Hold for a DecadeMotley Fool·Jun 16, 2026
- Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026Yahoo Finance·Jun 15, 2026
- Rapport ‘fully prepared’ to launch seizure drug solo, CEO saysBiopharmadive·Jun 12, 2026
- Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsightYahoo Finance·Jun 11, 2026
- Norges Bank Makes New $90.49 Million Investment in Axsome Therapeutics, Inc. $AXSMMarketBeat·Jun 6, 2026
- Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS PipelineMarketbeat·Jun 6, 2026
- Does SUNOSI Patent Peace And New Migraine Data Change The Bull Case For Axsome Therapeutics (AXSM)?Yahoo Finance·Jun 5, 2026
- Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?Yahoo Finance·Jun 5, 2026
- Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?Yahoo Finance·Jun 4, 2026
- Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific MeetingYahoo Finance·Jun 4, 2026
- Otsuka showcases kidney drug data; Pfizer cuts an AI dealBiopharmadive·Jun 4, 2026
- Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?Yahoo Finance·Jun 3, 2026
- Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent LitigationYahoo Finance·Jun 3, 2026
- Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness MonthYahoo Finance·Jun 1, 2026
- Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price MomentumSimply Wall Street·May 30, 2026
- Axsome Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·May 27, 2026
- Should New AUVELITY Anxious-Distress Data From ASCP 2026 Require Action From Axsome (AXSM) Investors?Simply Wall Street·May 26, 2026
- Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual MeetingYahoo Finance·May 26, 2026
- A Look At Axsome Therapeutics (AXSM) Valuation After AUVELITY Alzheimer’s Agitation Launch Plans And Earnings UpdateSimply Wall Street·May 16, 2026
- Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.comInvesting.com Nigeria·May 14, 2026
- Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation LaunchMarketbeat·May 12, 2026
- Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market LeadersYahoo Finance·May 8, 2026
- 3 Stocks Poised to Disrupt the Healthcare Market by 2030Motley Fool·May 8, 2026
- Assessing Axsome Therapeutics (AXSM) Valuation After Strong Recent Share Price MomentumYahoo Finance·May 7, 2026
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4GlobeNewswire Inc.·Apr 8, 2026
- Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool·Mar 25, 2026
All 29 articles loaded
Price Data
Open$245.60
Previous Close$241.97
Day High$246.76
Day Low$242.73
52 Week High$260.19
52 Week Low$96.09
52-Week Range
$96.09$260.19
$242.89
Fundamentals
Market Cap$12.8B
P/E Ratio—
EPS$-3.72
Dividend Yield—
Dividend / Share—
ROE-349.4%
Profit Margin-26.6%
Debt / Equity—
Trading
Volume93K
Avg Volume (10D)—
Shares Outstanding51.5M
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—